https://www.selleckchem.com/products/ldk378.html Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19 and allergy, focusing on the following topics virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development and epidemiology. Over 140 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.The present study is focused on the integration of microreactors to synthesize visible-light active nano-photocatalysts for inline photocatalytic degradation of organic dye and antibacterial activity. A wire assisted and a rapid laser micromachining technique have been employed for the fabrication of polydimethylsiloxane (PDMS) and poly(methyl methacrylate) (PMMA) based microreactors respectively. By varying the design and chemical reagents involved, different sizes of visible light active Ag2 S nanoparticles were prepared via a continuous microfluidics approach using fabricated microreactors. When polyvinylpyrrolidone (PVP) was utilized as the capping agent during the reaction, smaller particles of the size of ~15nm were observed. The photocatalytic performance of these nanoparticles has been evaluated inline by employing the single inlet planar microreactor as a function of flow rate and channel length. The photocatalyst durability test and a comparative photocatalytic efficiency study between the microreactor and the conventional beaker reactor have also been carried out. Under visible light, these nanoparticles exhibit a remarkable enhancement of ~94.5% in the inline microreactor based photocatalytic degradation of methylene blue dye.